Article snapshot taken from Wikipedia with creative commons attribution-sharealike license.
Give it a read and then ask your questions in the chat.
We can research this topic together.
You can help expand this article with text translated from the corresponding article in German. (April 2013) Click for important translation instructions.
View a machine-translated version of the German article.
Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Misplaced Pages.
Consider adding a topic to this template: there are already 2,142 articles in the main category, and specifying|topic= will aid in categorization.
Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing German Misplaced Pages article at ]; see its history for attribution.
You may also add the template {{Translated|de|Heinrich Hörlein}} to the talk page.
He was the son of the farmer Heinrich Hörlein and his wife, Philippina (née Dürk). After attending school in Alzey and Darmstadt, he began studying chemistry at the university in Darmstadt in 1900 and continued his studies in 1902 in Jena, where he received his doctoral degree in 1903. After that, he worked as an assistant to his dissertation advisor, Ludwig Knorr, until joining Bayer’s research laboratory at Elberfeld in 1909. There he was promoted rapidly: in 1911, he was entrusted with the supervision of the pharmaceutical laboratory, where he discovered the soporific Luminal in 1912. He was made an authorized signatory in 1914, a deputy director in 1919, and an alternate member of Bayer’s managing board in 1921. After the formation of the conglomerate I.G. Farben, he was made an alternate member of the managing board here as well in 1926, as head of pharmaceutical research in Elberfeld. The same year, the University of Munich awarded him an honorary medical degree and the title Dr. med. h.c.
Trial in Nurnberg